Key Stats
Key stats represent essential financial metrics and indicators used to evaluate a company's performance and potential investment opportunities.
Stock Score/grades
The Stock Score/Grades evaluate bankruptcy risk and assess the financial strength and fundamental health of a company
- Altman Z Score 17.02
- Piotroski Score 3.00
- Grade Buy
- Symbol (SGMT)
- Company Sagimet Biosciences Inc.
- Price $5.94
- Changes Percentage (-4.03%)
- Change -$0.25
- Day Low $5.72
- Day High $6.24
- Year High $20.71
Sagimet Biosciences Inc., a clinical-stage biopharmaceutical company, develops therapeutics called fatty acid synthase (FASN) inhibitors for the treatment of diseases that result from dysfunctional lipid metabolism pathways. Its lead drug candidate is Denifanstat, a FASN inhibitor for the treatment of nonalcoholic steatohepatitis and acne. The company is also developing TVB-3567, a FASN inhibitor for the treatment of various types of cancers. The company was formerly known as 3-V Biosciences, Inc. and changed its name to Sagimet Biosciences Inc. in August 2019. Sagimet Biosciences Inc. was incorporated in 2006 and is headquartered in San Mateo, California.
- Last Earnings
- Ex-Dividend for 5/16 Dividend
- Dividend Payable
- Today N/A
- Next Earnings (Estimated) 11/11/2024
- Fiscal Year End N/A
- Average Stock Price Target $6.00
- High Stock Price Target $6.00
- Low Stock Price Target $6.00
- Potential Upside/Downside N/A
- Consensus Rating Neutral
- Rating Score (0-4) N/A
- Research Coverage N/A
- EPS (Most Recent Fiscal Year) -$0.87
- Trailing P/E Ratio -5.4
- Forward P/E Ratio -5.4
- P/E Growth -5.4
- Net Income $-27,876,000
Income Statement
Quarterly
Annual
Latest News of SGMT
The Latest News section aggregates recent news posts from various news outlets, offering a comprehensive overview of the most recent developments related to the topic.
-
Sagimet Biosciences Inc. (SGMT): Should You Buy This New Penny Stock Now?
A list of top new penny stocks includes Sagimet Biosciences Inc. (NASDAQ:SGMT) due to its potential in the biopharmaceutical industry with a focus on metabolic dysfunction disorders....
By Yahoo! Finance | 2 months ago -
Sagimet Biosciences (NASDAQ:SGMT) Is In A Good Position To Deliver On Growth Plans
Despite a company losing money, shareholders can still profit by investing in a good business at the right price. Sagimet Biosciences, with a cash runway of 8.5 years and reduced cash burn rate, appea...
By Yahoo! Finance | 4 months ago